Thetis Pharmaceuticals LLC is a biopharmaceutical company developing novel "immuno-resolving" therapies to treat inflammatory bowel disease (IBD).
In contrast to existing IBD therapies that work by inhibiting key steps in the inflammatory process, Thetis agents offer a unique therapeutic approach based on resolving inflammation and promoting tissue regeneration without suppressing normal immune function. Our agents deliver endogenous bioactive lipids that play a critical role in regulating the inflammatory response. Through its proprietary HEALER™ technology platform, Thetis unlocks the potent pharmacology of these lipids as new molecules with enhanced stability, formulation, and manufacturing properties and strong patent protection.
Thetis has two candidates in preclinical development. TP-317 is a unique derivative of a Specialized Pro-Resolving Mediator, a class of bioactive lipids that have been shown to activate innate pathways to control gastrointestinal inflammation and gut mucosal immune responses at very small therapeutic doses. TP-317 has the potential to be an induction and maintenance agent for patients failing first-line 5-ASA therapy as an alternative to immunosuppressive "step-up" therapies that pose a greater risk of significant side effects. TP-252 is a unique derivative of eicosapentaenoic acid, which has been shown in an academic Phase 2 trial to be effective in treating ulcerative colitis. TP-252 is targeted as adjunct over 5-ASA therapy to avoid escalation to step-up therapies.